
With the pharmaceutical market expected to grow significantly in the coming years, Eli Lilly and Company (LLY) and its pursuit of strategic acquisitions in this large and growing market could be a boon for shareholders.
LLY’s chair and CEO, David A. Ricks, stated, “Core business growth drove solid first-quarter financial results and a strong start for Lilly in 2023, which includes pipeline progress led by positive SURMOUNT-2 data for tirzepatide in obesity.”